Redhill Biopharma Ltd (RDHL)

Currency in USD
2.170
-0.180(-7.66%)
Closed·
After Hours
2.258+0.088(+4.07%)
·
RDHL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RDHL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.1202.450
52 wk Range
1.71020.275
Key Statistics
Prev. Close
2.17
Open
2.36
Day's Range
2.12-2.45
52 wk Range
1.71-20.275
Volume
621.63K
Average Volume (3m)
512.18K
1-Year Change
-77.27%
Book Value / Share
-3.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RDHL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Redhill Biopharma Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Redhill Biopharma Ltd Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Employees
35

Compare RDHL to Peers and Sector

Metrics to compare
RDHL
Peers
Sector
Relationship
P/E Ratio
−0.6x−0.1x−0.5x
PEG Ratio
0.010.050.00
Price/Book
−1.1x−0.1x2.6x
Price / LTM Sales
0.6x1.6x3.2x
Upside (Analyst Target)
-134.2%42.7%
Fair Value Upside
Unlock26.8%5.8%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RDHL Income Statement

People Also Watch

1.000
WINT
+1.01%
0.820
PMN
-26.79%
2.360
SQNS
-2.88%
2.120
UAVS
+9.28%
2.750
INDO
+0.73%

FAQ

What Stock Exchange Does Redhill ADR Trade On?

Redhill ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Redhill ADR?

The stock symbol for Redhill ADR is "RDHL."

What Is the Redhill ADR Market Cap?

As of today, Redhill ADR market cap is 4.98M.

What Is Redhill ADR's Earnings Per Share (TTM)?

The Redhill ADR EPS (TTM) is -6.71.

When Is the Next Redhill ADR Earnings Date?

Redhill ADR will release its next earnings report on 13 Aug 2025.

From a Technical Analysis Perspective, Is RDHL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Redhill ADR Stock Split?

Redhill ADR has split 2 times.

How Many Employees Does Redhill ADR Have?

Redhill ADR has 35 employees.

What is the current trading status of Redhill ADR (RDHL)?

As of 23 Jul 2025, Redhill ADR (RDHL) is trading at a price of 2.17, with a previous close of 2.17. The stock has fluctuated within a day range of 2.12 to 2.45, while its 52-week range spans from 1.71 to 20.28.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.